TY - JOUR
T1 - Outcome of COVID-19 in allogeneic stem cell transplant recipients
T2 - Results from the EPICOVIDEHA registry
AU - Busca, Alessandro
AU - Salmanton-García, Jon
AU - Marchesi, Francesco
AU - Farina, Francesca
AU - Seval, Guldane Cengiz
AU - van Doesum, Jaap
AU - de Jonge, Nick
AU - Bahr, Nathan C.
AU - Maertens, Johan
AU - Meletiadis, Joseph
AU - Fracchiolla, Nicola S.
AU - Weinbergerová, Barbora
AU - Verga, Luisa
AU - Ráčil, Zdeněk
AU - Jiménez, Moraima
AU - Glenthøj, Andreas
AU - Blennow, Ola
AU - Tanase, Alina Daniela
AU - Schönlein, Martin
AU - Prezioso, Lucia
AU - Khanna, Nina
AU - Duarte, Rafael F.
AU - Žák, Pavel
AU - Nucci, Marcio
AU - Machado, Marina
AU - Kulasekararaj, Austin
AU - Espigado, Ildefonso
AU - de Kort, Elizabeth
AU - Ribera-Santa Susana, José-María
AU - Marchetti, Monia
AU - Magliano, Gabriele
AU - Falces-Romero, Iker
AU - Ilhan, Osman
AU - Ammatuna, Emanuele
AU - Zompi, Sofia
AU - Tsirigotis, Panagiotis
AU - Antoniadou, Anastasia
AU - Zambrotta, Giovanni Paolo Maria
AU - Nordlander, Anna
AU - Karlsson, Linda Katharina
AU - Hanakova, Michaela
AU - Dragonetti, Giulia
AU - Cabirta, Alba
AU - Berg Venemyr, Caroline
AU - Gräfe, Stefanie
AU - van Praet, Jens
AU - Tragiannidis, Athanasios
AU - Petzer, Verena
AU - López-García, Alberto
AU - Itri, Federico
AU - Groh, Ana
AU - Gavriilaki, Eleni
AU - Dargenio, Michelina
AU - Rahimli, Laman
AU - Cornely, Oliver A.
AU - Pagano, Livio
N1 - Funding Information: EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223). The funder of the study had no role in study design, data analysis, interpretation, or writing of the report. All authors had full access to the data and had final responsibility for the decision to submit for publication. Publisher Copyright: Copyright © 2023 Busca, Salmanton-García, Marchesi, Farina, Seval, Van Doesum, De Jonge, Bahr, Maertens, Meletiadis, Fracchiolla, Weinbergerová, Verga, Ráčil, Jiménez, Glenthøj, Blennow, Tanase, Schönlein, Prezioso, Khanna, Duarte, Žák, Nucci, Machado, Kulasekararaj, Espigado, De Kort, Ribera-Santa Susana, Marchetti, Magliano, Falces-Romero, Ilhan, Ammatuna, Zompi, Tsirigotis, Antoniadou, Zambrotta, Nordlander, Karlsson, Hanakova, Dragonetti, Cabirta, Berg Venemyr, Gräfe, Van Praet, Tragiannidis, Petzer, López-García, Itri, Groh, Gavriilaki, Dargenio, Rahimli, Cornely, Pagano and EPICOVIDEHA Consortium.
PY - 2023
Y1 - 2023
N2 - Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.
AB - Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.
KW - COVID-19 infection
KW - SARS-CoV-2
KW - allogeneic HSCT
KW - hematological malignances
KW - immunocompromised patients
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85149866062&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36911708
U2 - https://doi.org/10.3389/fimmu.2023.1125030
DO - https://doi.org/10.3389/fimmu.2023.1125030
M3 - Article
C2 - 36911708
SN - 1664-3224
VL - 14
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 1125030
ER -